IDT Australia EBIT per Share
The EBIT per Share of IDT Australia (IDT.AX) as of Aug 7, 2026 is -0.02 AUD. In the previous year, EBIT per Share was -0.02 AUD — a change of 0.21% (lower).
Get this data via API
Financial Data API
EBIT per Share
-0.02AUD
YoY
0.21%
Last updated:
EBIT per Share of IDT Australia is 2026 -0.02 AUD. EBIT per Share of IDT Australia was 2025 -0.02 AUD. It decreases by 0.21% lower compared to the previous year.
Access this data via the Eulerpool API
IDT Australia Stock analysis
What does IDT Australia do? IDT Australia Ltd is a leading company in the development and manufacturing of pharmaceutical active ingredients and other biological products. The company was founded in 1974 and is headquartered in Melbourne, Australia. For over 40 years, IDT has been working to develop innovative solutions and products to improve the health and well-being of people worldwide.
The history of IDT Australia Ltd began with the goal of Walter and Elke Kortschak to establish a company that produces high-quality pharmaceutical active ingredients. The company started its active ingredient production in a small facility in Melbourne and was able to grow quickly. In the following years, IDT expanded into various areas of the pharmaceutical industry and is now a leading manufacturer of drugs, vaccines, and diagnostics.
IDT Australia Ltd is divided into four main areas: active ingredients, biologics, diagnostics, and vaccines. Each of these areas has unique products and services offered by the company.
In the field of active ingredients, IDT Australia Ltd offers a wide range of pharmaceutical active ingredients. The company specializes in the production of API's (Active Pharmaceutical Ingredients) used in the manufacturing of drugs. The product range includes strong painkillers to cancer drugs. IDT also produces custom active ingredients tailored to the specific needs of a customer.
In the field of biologics, IDT Australia Ltd specializes in the production of biological products. Here, the company offers an extensive range of products such as antibodies, enzymes, recombinant proteins, and more. These products are used in drug research and development and in diagnostics.
The diagnostics sector includes both diagnostic tests and test kits. IDT produces tests for a variety of conditions such as hypertension, diabetes, metabolic disorders, and infectious diseases. The diagnostics division of IDT has become an important part of the company, supporting accurate diagnosis, rapid decision-making, and optimal treatment of diseases.
The vaccines sector is one of the newest areas at IDT Australia Ltd. In this field, the company specializes in the production of vaccines against infectious diseases. This means that IDT is one of the few Australian companies with the capability to develop and produce vaccines. The company works closely with the Australian government, private health organizations, and other companies to ensure the development of effective vaccines against serious infectious diseases.
IDT Australia Ltd takes pride in offering products and services of the highest quality. The company is committed to meeting the requirements and expectations of its customers—and beyond. From the development of new medications to the production of high-quality active ingredients, biologics, diagnostics, and vaccines, IDT carefully monitors all production processes. The company continually invests in research and development to improve processes and products.
The work of IDT Australia Ltd has received countless awards and recognition, both in Australia and internationally. The company is among the ten Australian companies represented in the Global Cleantech 100 in 2017. IDT Australia Ltd also holds the record for the fastest order processing for a medical device in Australia. However, the success of the company is not only measured by its industry and customer recognition, but also by the commitment of its employees to research, innovation, and improved health worldwide.
Overall, IDT Australia Ltd plays a significant role in the development and manufacturing of active ingredients, biologics, diagnostics, and vaccines. The products and services of the company have the potential to improve the lives of millions of people worldwide. IDT Australia Ltd is on track to continue being a driving force in the development and production of new products in the pharmaceutical industry. IDT Australia is one of the most popular companies on Eulerpool.
Frequently Asked Questions about IDT Australia stock
EBIT per Share of IDT Australia is -0.02 AUD in 2026.
EBIT per Share of IDT Australia changed from -0.02 AUD to -0.02 AUD, representing a 0.21% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of EBIT per Share IDT Australia since 2006 – with annual values, charts, and detailed analysis.
EBIT per Share measures operating profit allocated to each outstanding share.
Access this data via the Eulerpool API
Income Statement — IDT Australia
All Key Metrics — IDT Australia
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth